Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma.

2.50
Hdl Handle:
http://hdl.handle.net/10541/99259
Title:
Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma.
Authors:
Woll, Penella J; Crowther, Derek; Johnson, P W; Soukop, M; Harper, P G; Harris, Martin; Brampton, M H; Newlands, E S
Abstract:
Temozolomide, an imidazotetrazine derivative, was given to 18 patients with low-grade non-Hodgkin's lymphoma (NHL) at a dose of 750 mg m-2 orally, divided over five consecutive days, escalated to 1000 mg m-2 over 5 days (i.e. 200 mg m-2 day-1) if no significant myelosuppression was noted at day 22 of the 28 day cycle. Fifty-six treatment cycles were given to 18 patients. The drug was well tolerated. Only one partial tumour response was documented. The patients were heavily pretreated but had chemoresponsive disease, as shown by a response rate of 69% among 13 patients who went on to receive alternative cytotoxic regimens. We conclude that temozolomide given in this schedule is inactive in previously treated low-grade NHL.
Affiliation:
CRC Department of Medical Oncology, Christie Hospital, Manchester, UK.
Citation:
Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma. 1995, 72 (1):183-4 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
Jul-1995
URI:
http://hdl.handle.net/10541/99259
PubMed ID:
7599050
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorWoll, Penella Jen
dc.contributor.authorCrowther, Dereken
dc.contributor.authorJohnson, P Wen
dc.contributor.authorSoukop, Men
dc.contributor.authorHarper, P Gen
dc.contributor.authorHarris, Martinen
dc.contributor.authorBrampton, M Hen
dc.contributor.authorNewlands, E Sen
dc.date.accessioned2010-05-19T09:50:08Z-
dc.date.available2010-05-19T09:50:08Z-
dc.date.issued1995-07-
dc.identifier.citationPhase II trial of temozolomide in low-grade non-Hodgkin's lymphoma. 1995, 72 (1):183-4 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid7599050-
dc.identifier.urihttp://hdl.handle.net/10541/99259-
dc.description.abstractTemozolomide, an imidazotetrazine derivative, was given to 18 patients with low-grade non-Hodgkin's lymphoma (NHL) at a dose of 750 mg m-2 orally, divided over five consecutive days, escalated to 1000 mg m-2 over 5 days (i.e. 200 mg m-2 day-1) if no significant myelosuppression was noted at day 22 of the 28 day cycle. Fifty-six treatment cycles were given to 18 patients. The drug was well tolerated. Only one partial tumour response was documented. The patients were heavily pretreated but had chemoresponsive disease, as shown by a response rate of 69% among 13 patients who went on to receive alternative cytotoxic regimens. We conclude that temozolomide given in this schedule is inactive in previously treated low-grade NHL.en
dc.language.isoenen
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAntineoplastic Agents-
dc.subject.meshDacarbazine-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshLymphoma, Non-Hodgkin-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.titlePhase II trial of temozolomide in low-grade non-Hodgkin's lymphoma.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Christie Hospital, Manchester, UK.en
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.